Roderick MacLeod Appointed Chief Financial Officer of Nevro

Roderick MacLeod has been appointed Chief Financial Officer of Nevro Corp, effective June 15, 2020, with global responsibility for Finance, IT and Customer Service.  Mr. MacLeod succeeds Andrew Galligan, who is retiring but will remain with the Company during a transition period.

“Roderick MacLeod is a proven leader with a track record of success in finance and operations leadership.  We are pleased that Rod is joining the Nevro executive team at a point in our history where his extensive financial, strategic and industry experience will help us accelerate toward long-term sustainable growth and strong financial performance for our shareholders,” said D. Keith Grossman, Chairman, CEO and President, Nevro.

“I’m very pleased to join Nevro and I view this as an exciting opportunity to continue to build a great company while helping patients who suffer from chronic pain,” said Rod MacLeod.  “I look forward to working closely with Keith and the rest of the Nevro team to execute on the Company’s growth strategy.”

Regarding Andrew Galligan’s retirement Grossman added, “Nevro has benefitted tremendously from Andrew’s leadership over the past decade and he has played a vital role in establishing a solid financial and operational foundation for the Company.  On behalf of the entire organization, I want to thank Andrew for his many accomplishments as CFO.  I also want to thank Andrew personally for being a great resource for me as I came on board, and for remaining with the Company during this transition period.”

“I’d like to thank Keith and the entire Nevro team – it’s truly been an honor to be a part of Nevro for these ten years,” said Andrew Galligan, Chief Financial Officer, Nevro.  “I’m proud of all that we’ve accomplished together and I’m confident that the Company is well positioned for future growth and success.”

Roderick MacLeod joins Nevro with more than 25 years of experience in financial and executive leadership roles in healthcare and technology.  Most recently he served as Vice President of Finance of Stryker Endoscopy, a $1.8 billion division of Stryker Corp that develops and manufactures medical devices used in minimally invasive surgical procedures.  During his 16-year career at Stryker Endoscopy, Mr. MacLeod played a key role in growing the division from $500 million to $1.8 billion in revenue.  Prior to this role, Mr. MacLeod was Controller for Stryker Endoscopy.  Previously, Mr. MacLeod was Vice President of Finance and Administration at Lumenare Networks, a Sunnyvale-based software company.  Earlier in his career, Mr. MacLeod was Financial Manager/Controller at United Airlines and was a Senior Operational and Audit Consultant at Arthur Andersen & Co.  Rod MacLeod graduated from the J.L. Kellogg Graduate School of Management at Northwestern University with a Master of Management degree and received his Bachelor of Arts degree in Economics from Harvard University.

SourceNevro

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”